BioSpace News Archive

Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2 Inflammatory specialty diseases, today announced that it will present a poster demonstrating the ability of LNR 125.38 (“LNR125”) to inhibit Type 2 inflammation in models of asthma caused by both allergy and respiratory viral infection at the upcoming American Thoracic Society Meeting.

The Anesthesia & Respiratory Devices market size is expected to hit around US$ 50.4 billion by 2028 and is projected to grow at a CAGR of 7.6% during forecast period 2021 to 2028.

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, May 17, 2022, to discuss the company’s financial results for the first quarter ended March 31, 2022.

The Bariatric Surgery Devices market was valued at US$ 12.3 billion in 2020 and is expected to hit around US$ 12.8 billion by 2030 with a CAGR of 20.15% during forecast period 2021 to 2030.

Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth.

The rise in demand for topical dermatological medications, such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients, to treat acne is a major factor driving the market.

A growing number of applications and a significant demand for technologically advanced three-dimensional imaging technologies are driving the market for micro computed tomography (CT). In addition, the increasing use of micro-CT in research is expected to boost the market growth.

Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced that positive interim results from a Phase 2a trial of its investigational novel gene therapy, URO-902, were presented Friday at the 2022 annual meeting of the American Urological Association (AUA2022).

AESARA (www.aesara.com) is pleased to announce their attendance and poster presentations this ISPOR 2022 held in Washington, D.C. from May 16 – 18, 2022.

Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that Health Canada has accepted the filing of a Supplement to a New Drug Submission for an investigational oral formulation of edaravone indicated for the treatment of amyotrophic lateral sclerosis.